Spectranetics Refocuses On CLI Indication After PELA Submission Setback
This article was originally published in The Gray Sheet
Executive Summary
Spectranetics is considering whether to continue to pursue a claudication indication for its CVX-300 excimer laser in light of disappointing peripheral excimer laser angioplasty (PELA) trial results
You may also be interested in...
Spectranetics CVX-300 Panel Review Hindered By Historical Control Arm
FDA should have discouraged Spectranetics from conducting a non-randomized trial for critical limb ischemia (CLI), Circulatory System Devices Panel members asserted Oct. 2
Spectranetics CVX-300 Panel Review Hindered By Historical Control Arm
FDA should have discouraged Spectranetics from conducting a non-randomized trial for critical limb ischemia (CLI), Circulatory System Devices Panel members asserted Oct. 2
Hologic Selenia With CAD Approval Expected By Year End; Stock Up 17%
Hologic's strategy of pursuing co-development and distribution deals for its digital mammography system, combined with its shift to direct sales, appears to be striking a favorable chord with Wall Street onlookers